Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib adjuvant therapy after curative resection for high-risk recurrent hepatocellular carcinoma
ChiCTR1900022973Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Recurrence-free survival. Planned start May 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900022973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022973.